Jennifer L Sorrell, MD
Dermatology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · Peninsula Dermatology Medical Group Inc
Looking this up.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sorrell’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A136518 · Current
Licensed to practise in California · since 2015 · expires 2029-02-28 · Temple University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$176,857
Medicare paid this office $176,857 for 603 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 428 | $50,006 | $77 |
| Biopsy of related skin growth, first growth | 214 | $22,430 | $86 |
| Destruction of precancer skin growth, 1 growth | 261 | $18,946 | $49 |
| Destruction of skin growth, 1-14 growths | 130 | $17,426 | $111 |
| Return visit (30+ min) | 66 | $9,811 | $117 |
See all 17 services
| Short return visit (20+ min) | 428 | $50,006 | $77 |
| Biopsy of related skin growth, first growth | 214 | $22,430 | $86 |
| Destruction of precancer skin growth, 1 growth | 261 | $18,946 | $49 |
| Destruction of skin growth, 1-14 growths | 130 | $17,426 | $111 |
| Return visit (30+ min) | 66 | $9,811 | $117 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 18 | $9,278 | None |
| Application of light with debridement to destroy precancer skin growth | 18 | $8,144 | $291 |
| New patient visit (30+ min) | 91 | $8,121 | $89 |
| Destruction of precancer skin growth, 2-14 growths | 200 | $6,869 | $7 |
| Pathology examination of tissue using a microscope, intermediate complexity | 103 | $5,702 | $20 |
| Short return visit | 83 | $4,402 | $46 |
| Biopsy of related skin growth, each additional growth | 50 | $3,544 | $51 |
| Punch biopsy, first skin growth | 21 | $2,443 | $116 |
| Injection into skin growth, 1-7 growths | 19 | $1,015 | $41 |
| Biopsy of ear | 11 | $794 | $72 |
| New patient visit (15+ min) | 11 | $562 | $51 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 22 | $35 | None |
Procedures Medicare counted
| Removal of skin lesions | 562 | More than 88% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 226 | More than 87% of doctors who do this |
Who their Medicare patients are
603 Original Medicare patients in 2024. Average age 77 · Women 57% · Health risk score 0.88. At or below the middle of the specialty; the typical pediatric medicine clinician is at 1.4.
Conditions among them: High blood pressure 63% · Coronary heart disease 19% · Diabetes 17% · Atrial fibrillation 17% · Chronic kidney disease 16% · Cancer 16% · Heart failure 11% · Depression 9% · COPD 7% · Dementia 4% · Stroke 2%.
The office billed $335,686, Medicare allowed $241,415 and paid $176,857; for 3,363 services of 37 kinds; $9,314 of it was for drugs given in the office and $167,543 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 603 | 3,363 | 77 | 0.88 | $335,686 | $176,857 |
| 2023 | 428 | 3,388 | 77 | 0.90 | $351,275 | $153,213 |
| 2022 | 316 | 1,939 | 76 | 0.87 | $214,963 | $94,131 |
| 2021 | 237 | 1,512 | 76 | 0.94 | $177,040 | $79,963 |
| 2020 | 294 | 1,797 | 76 | 0.95 | $193,235 | $87,361 |
| 2019 | 163 | 706 | 76 | 1.00 | $79,769 | $37,520 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Short return visit (20+ min) | 324 | $43,013 | $75 |
| Biopsy of related skin growth, first growth | 209 | $24,271 | $85 |
| Destruction of precancer skin growth, 1 growth | 240 | $18,881 | $47 |
| Destruction of skin growth, 1-14 growths | 115 | $16,625 | $108 |
| Destruction of precancer skin growth, 2-14 growths | 196 | $9,622 | $7 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 27 | $5,983 | $166 |
| Biopsy of related skin growth, each additional growth | 64 | $5,273 | $51 |
| Return visit (30+ min) | 38 | $4,911 | $107 |
| Short return visit | 74 | $4,414 | $51 |
| New patient visit (30+ min) | 46 | $3,997 | $87 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $2,895 | $170 |
| Punch biopsy, first skin growth | 21 | $2,578 | $123 |
| Biopsy of ear | 14 | $1,074 | $72 |
| Injection into skin growth, 1-7 growths | 12 | $855 | $37 |
| New patient visit (15+ min) | 12 | $636 | $53 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $17 | None |
2022: 12 services
| Short return visit (20+ min) | 228 | $28,885 | $76 |
| Destruction of skin growth, 1-14 growths | 85 | $13,730 | $104 |
| Biopsy of related skin growth, first growth | 108 | $11,284 | $87 |
| Destruction of precancer skin growth, 1 growth | 150 | $9,737 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 113 | $4,937 | $7 |
| Short return visit | 58 | $3,758 | $51 |
| Return visit (30+ min) | 25 | $3,655 | $114 |
| New patient visit (30+ min) | 42 | $2,766 | $66 |
| Punch biopsy, first skin growth | 20 | $2,336 | $111 |
| Destruction of precancer skin growth, 15 or more growths | 11 | $2,200 | $169 |
| Biopsy of related skin growth, each additional growth | 29 | $1,675 | $51 |
| Biopsy of ear | 11 | $939 | $78 |
2021: 11 services
| Short return visit (20+ min) | 161 | $20,194 | $76 |
| Destruction of skin growth, 1-14 growths | 72 | $13,108 | $103 |
| Biopsy of related skin growth, first growth | 109 | $12,131 | $89 |
| Destruction of precancer skin growth, 1 growth | 98 | $7,184 | $46 |
| Short return visit | 67 | $3,792 | $48 |
| Return visit (30+ min) | 24 | $3,357 | $112 |
| Destruction of precancer skin growth, 2-14 growths | 74 | $3,090 | $7 |
| New patient visit (30+ min) | 32 | $2,300 | $72 |
| Punch biopsy, first skin growth | 17 | $2,143 | $119 |
| Biopsy of related skin growth, each additional growth | 31 | $1,992 | $54 |
| All potassium hydroxide (koh) preparations | 12 | $82 | $6 |
2020: 11 services
| Short return visit (20+ min) | 155 | $16,489 | $64 |
| Biopsy of related skin growth, first growth | 120 | $10,996 | $80 |
| Destruction of skin growth, 1-14 growths | 73 | $10,459 | $109 |
| Destruction of precancer skin growth, 1 growth | 116 | $7,281 | $43 |
| Return visit (30+ min) | 63 | $6,454 | $92 |
| Destruction of precancer skin growth, 2-14 growths | 100 | $3,540 | $6 |
| Biopsy of related skin growth, each additional growth | 30 | $2,118 | $54 |
| Short return visit | 46 | $1,998 | $35 |
| Punch biopsy, first skin growth | 17 | $1,995 | $117 |
| New patient visit (30+ min) | 24 | $1,899 | $79 |
| New patient visit (15+ min) | 33 | $1,889 | $57 |
2019: 10 services
| Biopsy of related skin growth, first growth | 65 | $6,254 | $89 |
| Short return visit (20+ min) | 67 | $5,936 | $68 |
| Destruction of skin growth, 1-14 growths | 33 | $4,104 | $103 |
| Destruction of precancer skin growth, 1 growth | 64 | $3,826 | $48 |
| Short return visit | 58 | $2,848 | $43 |
| Punch biopsy, first skin growth | 21 | $2,825 | $123 |
| Return visit (30+ min) | 22 | $2,143 | $97 |
| New patient visit (30+ min) | 18 | $1,590 | $88 |
| Destruction of precancer skin growth, 2-14 growths | 43 | $1,305 | $6 |
| Biopsy of related skin growth, each additional growth | 17 | $960 | $53 |
Medicaid work
$3,564 in 2019
Medicaid paid $3,564 for 72 billed services this clinician did in 2019, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 17 | $1,357 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 19 | $1,318 |
| Short return visit (20+ min) | 36 | $889 |
| 2019 | 72 | 3 | 22 | $3,564 |
| 2018 | 522 | 4 | 39 | $16,028 |
See the largest Medicaid services in earlier years
2018
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 154 | $8,605 |
| Short return visit (20+ min) | 329 | $6,120 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 24 | $1,188 |
| Short return visit | 15 | $115 |
Drugs they prescribed that Part D paid
$282,705
Pharmacies billed $282,705 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 558) in 2024. At or below the middle of the specialty; the typical pediatric medicine clinician is at 0%.
498 generic and 60 brand-name prescriptions · $282,705 in drug cost · 33 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 27 | $103,378 | $3,829 |
| Humira | 11 | $74,927 | $6,812 |
| Tacrolimus | 16 | $1,875 | $117 |
| Clobetasol Propionate | 40 | $1,590 | $40 |
| Triamcinolone Acetonide | 126 | $1,503 | $12 |
See all 15 drugs
| Dupixent | 27 | $103,378 | $3,829 |
| Humira | 11 | $74,927 | $6,812 |
| Tacrolimus | 16 | $1,875 | $117 |
| Clobetasol Propionate | 40 | $1,590 | $40 |
| Triamcinolone Acetonide | 126 | $1,503 | $12 |
| Mometasone Furoate | 42 | $967 | $23 |
| Fluocinonide | 18 | $825 | $46 |
| Ketoconazole | 41 | $527 | $13 |
| Doxycycline Hyclate | 27 | $447 | $17 |
| Clindamycin Phosphate | 11 | $388 | $35 |
| Minoxidil | 25 | $309 | $12 |
| Hydrocortisone | 13 | $164 | $13 |
| Valacyclovir | 20 | $162 | $8 |
| Mupirocin | 24 | $159 | $7 |
| Terbinafine | 14 | $75 | $5 |
Year by year
| 2024 | 558 | 256 | 0% (0) | 11% | $282,705 |
| 2023 | 490 | 184 | 0% (0) | 11% | $214,305 |
| 2022 | 371 | 144 | None | 8% | $105,355 |
| 2021 | 432 | 151 | 0% (0) | None | $38,779 |
| 2020 | 373 | 156 | 0% (0) | None | $13,675 |
| 2019 | 160 | 83 | 0% (0) | None | $7,887 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Dupixent | 23 | $85,191 | $3,704 |
| Tacrolimus | 24 | $2,725 | $114 |
| Clobetasol Propionate | 36 | $1,980 | $55 |
| Doxycycline Hyclate | 32 | $1,305 | $41 |
| Fluocinonide | 15 | $1,121 | $75 |
| Triamcinolone Acetonide | 85 | $1,089 | $13 |
| Ketoconazole | 42 | $886 | $21 |
| Mometasone Furoate | 30 | $792 | $26 |
| Clindamycin Phosphate | 18 | $347 | $19 |
| Minoxidil | 11 | $240 | $22 |
| Mupirocin | 25 | $236 | $9 |
| Valacyclovir | 15 | $160 | $11 |
| Hydrocortisone | 11 | $61 | $6 |
2022: 11 drugs
| Dupixent | 19 | $85,681 | $4,510 |
| Clobetasol Propionate | 29 | $3,115 | $107 |
| Doxycycline Hyclate | 26 | $1,737 | $67 |
| Tacrolimus | 11 | $1,246 | $113 |
| Triamcinolone Acetonide | 68 | $914 | $13 |
| Ketoconazole | 35 | $891 | $25 |
| Clindamycin Phosphate | 24 | $737 | $31 |
| Mometasone Furoate | 26 | $507 | $19 |
| Clindamycin Phos-Benzoyl Perox | 12 | $441 | $37 |
| Mupirocin | 15 | $94 | $6 |
| Hydrocortisone | 19 | $91 | $5 |
2021: 12 drugs
| Tacrolimus | 17 | $3,924 | $231 |
| Triamcinolone Acetonide | 108 | $1,284 | $12 |
| Clindamycin Phos-Benzoyl Perox | 13 | $1,200 | $92 |
| Fluocinolone Acetonide | 13 | $983 | $76 |
| Mometasone Furoate | 54 | $965 | $18 |
| Ketoconazole | 30 | $964 | $32 |
| Clobetasol Propionate | 17 | $886 | $52 |
| Clindamycin Phosphate | 21 | $788 | $38 |
| Doxycycline Hyclate | 30 | $598 | $20 |
| Fluocinonide | 11 | $508 | $46 |
| Terbinafine | 25 | $175 | $7 |
| Mupirocin | 15 | $137 | $9 |
2020: 10 drugs
| Triamcinolone Acetonide | 118 | $1,705 | $14 |
| Clobetasol Propionate | 12 | $976 | $81 |
| Ketoconazole | 30 | $725 | $24 |
| Mometasone Furoate | 38 | $697 | $18 |
| Fluocinonide | 11 | $601 | $55 |
| Clindamycin Phos-Benzoyl Perox | 13 | $573 | $44 |
| Clindamycin Phosphate | 16 | $526 | $33 |
| Doxycycline Hyclate | 19 | $254 | $13 |
| Mupirocin | 17 | $140 | $8 |
| Cephalexin | 12 | $119 | $10 |
2019: 2 drugs
| Triamcinolone Acetonide | 43 | $502 | $12 |
| Ketoconazole | 16 | $377 | $24 |
Money from drug and device companies
$1,429 in 2025
| 2025 | 14 | 71 | None | $1,429 |
| 2024 | 18 | 120 | None | $2,061 |
| 2023 | 17 | 151 | None | $3,015 |
| 2022 | 15 | 153 | None | $2,746 |
| 2021 | 21 | 134 | None | $2,740 |
| 2020 | 14 | 70 | None | $1,205 |
| 2019 | 11 | 30 | None | $635 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $226 | 7 payments
|
| Galderma Laboratories L.P. | Nemluvio | $213 | 9 payments
|
| Incyte | Opzelura | $183 | 8 payments
|
| Arcutis Biotherapeutics | Zoryve | $175 | 13 payments
|
| Lilly USA | Taltz | $160 | 11 payments
|
| Regeneron Healthcare Solutions | Dupixent | $101 | 4 payments
|
See all 71 published payments
| Arcutis Biotherapeutics | Meals · 2025-12-18 | Zoryve | $20 |
| Sun Pharmaceutical Industries | Meals · 2025-12-15 | Ilumya | $34 |
| Genzyme | Meals · 2025-12-12 | Dupixent | $31 |
| Incyte | Meals · 2025-12-10 | Opzelura | $12 |
| Regeneron Healthcare Solutions | Meals · 2025-12-06 | Dupixent | $27 |
| Incyte | Meals · 2025-12-04 | Opzelura | $5 |
| Regeneron Healthcare Solutions | Meals · 2025-11-22 | Dupixent | $19 |
| LEO Pharma | Meals · 2025-11-21 | Adbry | $15 |
| Incyte | Meals · 2025-11-14 | Opzelura | $22 |
| Ucb | Meals · 2025-11-04 | Bimzelx | $30 |
| Organon | Meals · 2025-10-13 | None | $12 |
| Organon | Meals · 2025-09-25 | Vtama | $1 |
| Organon | Meals · 2025-09-25 | Vtama | $4 |
| Organon | Meals · 2025-09-25 | Vtama | $5 |
| Organon | Meals · 2025-09-25 | Vtama | $5 |
| Organon | Meals · 2025-09-25 | Vtama | $20 |
| Janssen Biotech | Meals · 2025-09-24 | Tremfya | $22 |
| Abbvie | Meals · 2025-09-16 | Skyrizi | $26 |
| Incyte | Meals · 2025-09-12 | Opzelura | $29 |
| Abbvie | Meals · 2025-09-10 | Rinvoq | $23 |
| Incyte | Meals · 2025-09-06 | Opzelura | $30 |
| Arcutis Biotherapeutics | Meals · 2025-09-03 | Zoryve | $4 |
| Arcutis Biotherapeutics | Meals · 2025-09-03 | Zoryve | $4 |
| Arcutis Biotherapeutics | Meals · 2025-09-03 | Zoryve | $13 |
| Galderma Laboratories L.P. | Meals · 2025-09-02 | Nemluvio | $21 |
| Incyte | Meals · 2025-08-29 | Opzelura | $30 |
| Janssen Biotech | Meals · 2025-08-28 | Tremfya | $19 |
| Lilly USA | Meals · 2025-08-27 | Taltz | $29 |
| Lilly USA | Meals · 2025-08-22 | Taltz | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-08-19 | Dupixent | $31 |
| Abbvie | Meals · 2025-08-15 | Rinvoq | $22 |
| Janssen Biotech | Meals · 2025-08-12 | Tremfya | $17 |
| Arcutis Biotherapeutics | Meals · 2025-08-12 | Zoryve | $15 |
| Arcutis Biotherapeutics | Meals · 2025-07-25 | Zoryve | $36 |
| Arcutis Biotherapeutics | Meals · 2025-07-25 | Zoryve | $27 |
| Organon | Meals · 2025-07-17 | Vtama | $19 |
| Galderma Laboratories L.P. | Meals · 2025-07-10 | Nemluvio | $24 |
| Abbvie | Meals · 2025-06-27 | Skyrizi | $24 |
| Arcutis Biotherapeutics | Meals · 2025-06-26 | Zoryve | $4 |
| Regeneron Healthcare Solutions | Meals · 2025-06-24 | Dupixent | $25 |
| Lilly USA | Meals · 2025-06-20 | Taltz | $29 |
| Galderma Laboratories L.P. | Meals · 2025-06-06 | Nemluvio | $21 |
| Galderma Laboratories L.P. | Meals · 2025-05-23 | None | $21 |
| Janssen Biotech | Meals · 2025-05-21 | Tremfya | $23 |
| Janssen Biotech | Meals · 2025-05-09 | Tremfya | $23 |
| Incyte | Meals · 2025-05-07 | Opzelura | $28 |
| Arcutis Biotherapeutics | Meals · 2025-05-01 | Zoryve | $3 |
| Janssen Biotech | Education · 2025-04-30 | Tremfya | $99 |
| Galderma Laboratories L.P. | Meals · 2025-04-24 | Nemluvio | $30 |
| Ucb | Meals · 2025-04-10 | Bimzelx | $30 |
| Arcutis Biotherapeutics | Meals · 2025-03-27 | Zoryve | $7 |
| Lilly USA | Meals · 2025-03-21 | Taltz | $5 |
| Lilly USA | Meals · 2025-03-21 | Taltz | $4 |
| Lilly USA | Meals · 2025-03-21 | Taltz | $4 |
| Organon | Meals · 2025-03-20 | Vtama | $23 |
| Galderma Laboratories L.P. | Meals · 2025-03-18 | Nemluvio | $16 |
| Lilly USA | Meals · 2025-03-13 | Taltz | $18 |
| Amgen | Meals · 2025-03-13 | Otezla | $21 |
| Pfizer | Meals · 2025-03-12 | Litfulo | $26 |
| Incyte | Meals · 2025-03-05 | Opzelura | $27 |
| Arcutis Biotherapeutics | Meals · 2025-02-28 | Zoryve | $12 |
| Arcutis Biotherapeutics | Meals · 2025-02-28 | Zoryve | $10 |
| Janssen Biotech | Meals · 2025-02-26 | Tremfya | $23 |
| Lilly USA | Meals · 2025-02-03 | Taltz | $24 |
| Galderma Laboratories L.P. | Meals · 2025-01-30 | Nemluvio | $35 |
| Galderma Laboratories L.P. | Meals · 2025-01-24 | None | $18 |
| Lilly USA | Meals · 2025-01-22 | Taltz | $5 |
| Lilly USA | Meals · 2025-01-21 | Taltz | $5 |
| Lilly USA | Meals · 2025-01-21 | Taltz | $5 |
| Arcutis Biotherapeutics | Meals · 2025-01-21 | Zoryve | $18 |
| Galderma Laboratories L.P. | Meals · 2025-01-10 | Nemluvio | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,061
| Lilly USA | Taltz | $261 | 20 payments
|
| Incyte | Opzelura | $244 | 20 payments
|
| Abbvie | Skyrizi | $203 | 9 payments
|
| LEO Pharma | Adbry | $200 | 15 payments
|
| Ucb | Bimzelx | $147 | 12 payments
|
| Regeneron Healthcare Solutions | Dupixent | $136 | 2 payments
|
| Arcutis Biotherapeutics | Zoryve | $134 | 11 payments
|
| Genzyme | Dupixent | $131 | 5 payments
|
| Sun Pharmaceutical Industries | Ilumya | $114 | 4 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $92 | 4 payments
|
| Pfizer | Eucrisa | $92 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $68 | 2 payments
|
| Amgen | Otezla | $58 | 2 payments
|
| Dermavant Sciences | Vtama | $53 | 2 payments
|
| Biofrontera | Ameluz | $52 | 5 payments
|
| Galderma Laboratories L.P. | None | $40 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $21 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $14 | 1 payment
|
2023: $3,015
| AbbVie | Skyrizi | $496 | 24 payments
|
| Genzyme | Dupixent | $374 | 15 payments
|
| Pfizer | Eucrisa | $334 | 17 payments
|
| LEO Pharma | Adbry | $307 | 24 payments
|
| Lilly USA | Taltz | $295 | 13 payments
|
| Regeneron Healthcare Solutions | Dupixent | $289 | 12 payments
|
| Incyte | Opzelura | $220 | 15 payments
|
| Dermavant Sciences | Vtama | $161 | 6 payments
|
| Amgen | Otezla | $159 | 9 payments
|
| Sun Pharmaceutical Industries | Winlevi | $131 | 5 payments
|
| Janssen Biotech | Remicade | $74 | 3 payments
|
| Ucb | Bimzelx | $46 | 2 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $38 | 2 payments
|
| Galderma Laboratories L.P. | None | $25 | 1 payment
|
| Biofrontera | Ameluz | $25 | 1 payment
|
| Arcutis Biotherapeutics | None | $23 | 1 payment
|
| Journey Medical | None | $16 | 1 payment
|
2022: $2,746
| LEO Pharma | Adbry | $491 | 41 payments
|
| Janssen Biotech | Remicade | $381 | 21 payments
|
| Abbvie | Skyrizi | $333 | 15 payments
|
| Genzyme | Dupixent | $204 | 8 payments
|
| Regeneron Healthcare Solutions | Dupixent | $203 | 12 payments
|
| Ucb | Cimzia | $197 | 7 payments
|
| Lilly USA | Taltz | $197 | 10 payments
|
| Amgen | Otezla | $184 | 9 payments
|
| Incyte | Opzelura | $152 | 11 payments
|
| Novartis Pharmaceuticals | Cosentyx | $133 | 7 payments
|
| Sun Pharmaceutical Industries | Winlevi | $123 | 5 payments
|
| Pfizer | Eucrisa | $73 | 3 payments
|
| Galderma Laboratories L.P. | Epsolay | $39 | 2 payments
|
| Journey Medical | Qbrexza | $20 | 1 payment
|
| Genentech USA | Xolair | $15 | 1 payment
|
2021: $2,740
| AbbVie | Skyrizi | $476 | 21 payments
|
| Janssen Biotech | Remicade | $318 | 15 payments
|
| Lilly USA | Taltz | $272 | 13 payments
|
| LEO Pharma | Enstilar | $248 | 27 payments
|
| Ucb | Cimzia | $246 | 8 payments
|
| Regeneron Healthcare Solutions | Dupixent | $227 | 7 payments
|
| Sun Pharmaceutical Industries | Ilumya | $209 | 10 payments
|
| Genzyme | Dupixent | $150 | 7 payments
|
| Pfizer | Eucrisa | $92 | 4 payments
|
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $72 | 4 payments
|
| Mayne Pharma | None | $70 | 2 payments
|
| VYNE Pharmaceuticals | Amzeeq | $59 | 3 payments
|
| Janssen Scientific Affairs | Tremfya | $58 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $47 | 2 payments
|
| Amgen | Otezla | $46 | 2 payments
|
| Galderma Laboratories L.P. | Aklief | $38 | 2 payments
|
| Organogenesis | Puraply Antimicrobial | $33 | 1 payment
|
| Dermira | Qbrexza | $25 | 1 payment
|
| Incyte | Opzelura | $23 | 1 payment
|
| EPI Health | Cloderm | $16 | 1 payment
|
| Almirall | Seysara | $14 | 1 payment
|
2020: $1,205
| AbbVie | Skyrizi | $172 | 9 payments
|
| LEO Pharma | Enstilar | $159 | 18 payments
|
| Lilly USA | Taltz | $138 | 7 payments
|
| Genzyme | Dupixent | $137 | 6 payments
|
| Janssen Biotech | Remicade | $120 | 7 payments
|
| Pfizer | Eucrisa | $118 | 6 payments
|
| Mayne Pharma | Doryx | $116 | 5 payments
|
| VYNE Pharmaceuticals | Amzeeq | $58 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $44 | 2 payments
|
| Sun Pharmaceutical Industries | Ilumya | $41 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $34 | 2 payments
|
| Genentech USA | Erivedge | $24 | 1 payment
|
| Amgen | Otezla | $22 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $21 | 1 payment
|
2019: $635
| Novartis Pharmaceuticals | Cosentyx | $195 | 6 payments
|
| Pfizer | Eucrisa | $113 | 7 payments
|
| Lilly USA | Taltz | $86 | 4 payments
|
| AbbVie | Humira | $85 | 4 payments
|
| Sun Pharmaceutical Industries | Ilumya | $36 | 2 payments
|
| LEO Pharma | None | $30 | 1 payment
|
| Mayne Pharma | Doryx | $25 | 1 payment
|
| Janssen Biotech | Remicade | $19 | 2 payments
|
| Dermira | None | $19 | 1 payment
|
| DUSA Pharmaceuticals | Blu-U | $14 | 1 payment
|
| Galderma Laboratories L.P. | Epiduo Forte | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1487827861
- Licence
- CA A136518California A136518: Current · expires 2029-02-28
- Trained
- Temple University School of Medicine, 2005
- Group
- Sutter Bay Medical Foundation · Peninsula Dermatology Medical Group Inc
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207NP0225X (207NP0225X); Federal specialty code 207N00000X (207N00000X)
- Mailing address
- Po Box 276950, Sacramento, CA, 95827
- NPI first listed
- 2008-04-08
- NPI last updated
- 2025-10-31
- NPI record certified
- 2025-10-31
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 780 Welch Rd, Palo Alto, CA, 94304